- Home
- DTSS vs AIMD Comparison
DTSS vs AIMD Comparison
Compare DTSS & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTSS
- AIMD
- Stock Information
- Founded
- DTSS 2014
- AIMD 1984
- Country
- DTSS China
- AIMD United States
- Employees
- DTSS N/A
- AIMD N/A
- Industry
- DTSS Computer Software: Prepackaged Software
- AIMD Biotechnology: Pharmaceutical Preparations
- Sector
- DTSS Technology
- AIMD Health Care
- Exchange
- DTSS Nasdaq
- AIMD Nasdaq
- Market Cap
- DTSS 17.6M
- AIMD 16.9M
- IPO Year
- DTSS N/A
- AIMD N/A
- Fundamental
- Price
- DTSS $1.95
- AIMD $3.62
- Analyst Decision
- DTSS
- AIMD
- Analyst Count
- DTSS 0
- AIMD 0
- Target Price
- DTSS N/A
- AIMD N/A
- AVG Volume (30 Days)
- DTSS 39.1K
- AIMD 64.2K
- Earning Date
- DTSS 11-12-2025
- AIMD 11-14-2025
- Dividend Yield
- DTSS N/A
- AIMD N/A
- EPS Growth
- DTSS N/A
- AIMD N/A
- EPS
- DTSS N/A
- AIMD N/A
- Revenue
- DTSS $71,616,820.00
- AIMD $110,870.00
- Revenue This Year
- DTSS N/A
- AIMD N/A
- Revenue Next Year
- DTSS N/A
- AIMD N/A
- P/E Ratio
- DTSS N/A
- AIMD N/A
- Revenue Growth
- DTSS 198.70
- AIMD 70.25
- 52 Week Low
- DTSS $1.63
- AIMD $2.00
- 52 Week High
- DTSS $3.10
- AIMD $5.00
- Technical
- Relative Strength Index (RSI)
- DTSS 46.29
- AIMD 46.66
- Support Level
- DTSS $1.88
- AIMD $3.39
- Resistance Level
- DTSS $1.98
- AIMD $3.75
- Average True Range (ATR)
- DTSS 0.08
- AIMD 0.24
- MACD
- DTSS -0.00
- AIMD -0.06
- Stochastic Oscillator
- DTSS 57.14
- AIMD 21.90
About DTSS Datasea Inc.
Datasea Inc is a technology company. Its offers provides acoustic business services (focusing on high-tech acoustic technologies and applications such as ultrasound, infrasound, and Schumann resonance), 5G application services (5G AI multimodal digital business), and other products and services to various corporate and individual customers. The business activity of the group functions through China.
About AIMD Ainos Inc.
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.